Biogen has terminated the company’s asset purchase agreement with Karyopharm Therapeutics, putting a halt to the development of KPT-350 (BIIB100), which was being tested in Phase I as a treatment for amyotrophic lateral sclerosis (ALS).
https://www.pharmalive.com/wp-content/uploads/2021/05/Biogen-Pushes-Deeper-into-Gene-Therapy-with-Capsigen-Collaboration-BioSpace-5-11-21.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-06-16 11:39:522022-06-16 11:48:13Biogen halts ALS asset agreement with Karyopharm
